BioWorld

Aug. 5, 2005

View Archived Issues

FDA Committee Wants More Data For MT 100 In Migraine

ROCKVILLE, Md. - Prospects are growing dim for MT 100, a migraine drug developed by Pozen Inc. (BioWorld Today) Read More

ZymoGenetics Gets $135M To Advance rhThrombin

Read More

Par Dropping Advancis Deal After Amoxicillin Pulsys Miss

Read More

Predix IPO Seeks $70M; Phase III Program Starts

Read More